Activation of Wnt signaling has been implicated in gastric tumorigenesis, although mutations in APC (adenomatous polyposis coli), CTNNB1 (b-catenin) and AXIN are seen much less frequently in gastric cancer (GC) than in colorectal cancer. In the present study, we investigated the relationship between activation of Wnt signaling and changes in the expression of secreted frizzled-related protein (SFRP) family genes in GC. We frequently observed nuclear b-catenin accumulation (13/15; 87%) and detected the active form of b-catenin in most (12/16; 75%) GC cell lines. CpG methylation-dependent silencing of SFRP1, SFRP2 and SFRP5 was frequently seen among GC cell lines (SFRP1, 16/16, 100%; SFRP2, 16/ 16, 100%; SFRP5, 13/16, 81%) and primary GC specimens (SFRP1, 42/46, 91%; SFRP2, 44/46, 96%; SFRP5, 30/46, 65%), and treatment with the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine rapidly restored SFRP expression. Ectopic expression of SFRPs downregulated T-cell factor/lymphocyte enhancer factor transcriptional activity, suppressed cell growth and induced apoptosis in GC cells. Analysis of global expression revealed that overexpression of SFRP2 repressed Wnt target genes and induced changes in the expression of numerous genes related to proliferation, growth and apoptosis in GC cells. It thus appears that aberrant SFRP methylation is one of the major mechanisms by which Wnt signaling is activated in GC.
Introduction
The two known Wnt signaling pathways play essential roles in the regulation of cell proliferation, patterning and fate determination during normal developmental processes (Taketo, 2004) . The canonical pathway operates by stabilizing b-catenin, whereas the noncanonical pathway does not require b-catenin signaling and controls cell movement during morphogenesis. When the Wnt pathway is in its resting state, b-catenin is phosphorylated by glycogen synthase kinase 3b (GSK3b) within a protein complex that also includes casein kinase 1, adenomatous polyposis coli (APC) and Axin (Gregorieff and Clevers, 2005) . Phosphorylated bcatenin is immediately degraded via the ubiquitin proteasome pathway. Wnt binding to Frizzled (Fz) results in the activation of Dishevelled (Dsh), which inhibits the activity of GSK3b, resulting in dephosphorylation and stabilization of b-catenin, enabling it to accumulate within the nucleus, where it interacts with members of the T-cell factor/lymphocyte enhancer factor (TCF/LEF) family of transcription factors to stimulate the expression of target genes (Taketo, 2004) .
The Wnt/b-catenin pathway is known to be involved in tumorigenesis involving several cell types. For instance, the first mammalian Wnt isoform was identified based on its ability to promote mouse mammary tumorigenesis. APC is mutated in the germ line of individuals with familial adenomatous polyposis coli, and acquired mutations in APC, CTNNB1 (b-catenin) or AXIN2 initiate the majority of sporadic colorectal cancers (CRCs) (Gregorieff and Clevers, 2005) , at least in part because mutant APC and Axin are unable to assist GSK3b in phosphorylating/inactivating b-catenin. Similarly, mutations that lead to amino-acid substitution of the phosphorylated residues of b-catenin stabilize the protein. Either of these disruptions can lead to constitutive activation of the Wnt pathway.
Secreted frizzled-related proteins (SFRPs) are a family of five secreted glycoproteins that have been identified as modulators of the Wnt signaling pathway (Jones and Jomary, 2002) . SFRP family members all contain an N-terminal domain homologous to the cysteine-rich domain (CRD) of the Wnt receptor Fz and a C-terminal domain with some homology to netrin. In contrast to Fz family proteins, SFRPs lack a transmembrane region and the cytoplasmic domain required for signal transduction into the cells. This enables SFRPs to downregulate Wnt signaling by competing with Fz for Wnt binding via its CRD domain or by binding directly to Fz (Jones and Jomary, 2002) .
Up to now, it has been thought that mutations in APC, AXIN or CTNNB1 can cause constitutive signaling independent of the upstream signal from Wnt. In addition, we and others recently showed that SFRP family genes are frequent targets of aberrant DNA methylation in CRCs (Suzuki et al., 2002; Caldwell et al., 2004) , and we further showed that restoration of SFRP1, SFRP2 and SFRP5 in CRC cells attenuates Wnt signaling, even in the presence of downstream mutations . Since then, downregulation and methylation of SFRP genes have been identified in a variety of malignancies, including bladder cancer (Stoehr et al., 2004) , prostate cancer (Lodygin et al., 2005) , endometrial cancer (Risinger et al., 2005) , lung cancer (Fukui et al., 2005) , breast cancer (Veeck et al., 2006) , mesothelioma (Lee et al., 2004) and chronic lymphocytic leukemia (Liu et al., 2006) , which strongly suggests SFRPs function as tumor suppressor genes.
Gastric cancer (GC) is the second most common cause of death from cancer among both men and women in the world. Wnt signaling is involved in cell proliferation during development of the gut, and activation of the Wnt signaling pathway has been implicated in gastric tumorigenesis (Yuasa, 2003) . Indeed, persons carrying a germ-line mutation in APC have a 10-fold greater risk of developing GC than those without the mutation (Offerhaus et al., 1992) . However, mutations in APC or CTNNB1 are not often found in sporadic GC. For instance, our group previously examined 35 primary GC tissue samples and found no mutations in exon 3 of CTNNB1, whereas nuclear and cytoplasmic localization of b-catenin was observed in 23% of the tumors (Sasaki et al., 2001) . In the present study, therefore, our aim was to clarify the respective roles played by Wnt signaling and changes in SFRP expression in GC.
Results
Frequent activation of the canonical Wnt signaling pathway in GC To investigate the Wnt signaling status in GC, we initially analysed endogenous expression of b-catenin, as it is well known that canonical Wnt signaling allows stabilization of b-catenin and its accumulation in the nucleus (Taketo, 2004) . Immunofluorescent analysis of the cellular distribution of endogenous b-catenin revealed nuclear accumulation of the protein in 13 of 15 (87%) GC cells examined, whereas only six cells showed a membranous staining pattern (Table 1 ; Figure 1a) . Moreover, Western analysis using an anti-b-catenin antibody revealed detectable levels of endogenous bcatenin in all of the GC cell lines tested (Figure 1b) . Because activation of Wnt signaling leads to activation of b-catenin, we also utilized an antibody specific for the active form of b-catenin, which is dephosphorylated on Ser37 and Thr41. We detected active b-catenin in 12 of 16 cells, although the levels of expression varied considerably among the cell lines ( Figure 1b ; Table 1 ). When we then analysed TCF/LEF-regulated transcriptional activity in GC cells using a TCF/LEF-responsive 
Abbreviations: APC, adenomatous polyposis coli; GC, gastric cancer; M, methylated; NA, not available; ND, not done; RT-PCR, reverse transcriptase-polymerase chain reaction; SFRP, secreted frizzled-related protein; TCF, T-cell factor; U, unmethylated; U/M, both of methylated and unmethylated DNA was detected by MSP. a Weak basal expression was detectable by RT-PCR but 5-aza-dC treatment further increased the expression.
b Not available because of low transfection efficiency.
SFRPs methylation in gastric cancer M Nojima et al luciferase reporter vector (pGL3-OT), we found that in seven of the 14 (50%) cell lines tested, the luciferase activity of pGL3-OT was more than twofold higher than that of pGL3-OF, a negative control vector ( Figure 1c ; Table 1 ). Although the levels of TCF/LEF activity varied significantly among cell lines, we were able to observe some correspondence between luciferase activities and active b-catenin protein levels. Our results confirmed activation of the Wnt signaling pathway in half of the GC cell lines tested, although the apparent degree of activation varied. By contrast, to our knowledge, mutations in APC or CTNNB1 have been . Nuclei were visualized using 4 0 ,6-diamidino-2-phenylindole (DAPI; blue). (b) Western analysis of b-catenin in a set of GC cell lines using anti-b-catenin and anti-activeb-catenin antibodies. The same blot was reprobed for GAPDH as a loading control. (c) Luciferase assay carried out using a TCF/LEFresponsive reporter (pGL3-OT) and a negative control (pGL3-OF). Results are expressed as the pGL3-OT/pGL3-OF activity ratio after correction for transfection efficiency using renilla luciferase activity. Shown are means of four replications; the error bars represent standard deviations. Note that the TCF/LEF activities for the two cell lines with very elevated activities are not shown to scale.
SFRPs methylation in gastric cancer M Nojima et al reported for only four cell lines (Table 1) (Caca et al., 1999; Yokozaki, 2000; Sasaki et al., 2001; Ku and Park, 2005) . Of those, two (MKN74 and AZ521) were found to harbor the same mutation at codon 1450 of APC, a CGA-TGA transition, which leads to truncation of the protein (Sasaki et al., 2001) . A GGA-GAA transition at codon 34 (G34E) in CTNNB1 was found in AGS cells (Caca et al., 1999) , and an ACC-GCC change at codon 41 (T41A) in CTNNB1 was detected in SNU638 cells (Ku and Park, 2005) . In addition, CTNNB1 gene amplification was recently demonstrated in KatoIII cells (Suriano et al., 2005) . The two cell lines with APC mutations and KatoIII cells all showed typical features of constitutive activation of Wnt signaling, that is, dephosphorylation and nuclear accumulation of b-catenin and upregulation of TCF/ LEF-regulated transcription (Figure 1) . In SNU638 cells, however, only a low level of active b-catenin was observed ( Figure 1b) . It is plausible that the anti-activeb-catenin antibody failed to react with the mutant bcatenin, despite confocal microscopic and reporter assays confirming constitutive activation of Wnt signaling in SNU638 cells ( Figure 1c ; Table 1 ). Of note is fact that activation of the Wnt signaling pathway also was found in cell lines without APC or CTNNB1 gene abnormalities (Table 1) . Thus, our results suggest the involvement of mechanisms other than alterations in APC or CTNNB1 in the activation of Wnt signaling in GC cells.
Expression and methylation analysis of SFRP genes in GC cell lines
We previously demonstrated frequent inactivation of SFRP genes in CRC and suggested its involvement in the constitutive activation of Wnt signaling. We therefore hypothesized that a loss of SFRPs also may contribute to the activation of Wnt signaling in GC. To test that idea, we first used reverse transcriptasepolymerase chain reaction (RT-PCR) to analyse SFRP expression in a set of GC cell lines. Surprisingly, none of the 16 GC cell lines tested showed any expression of SFRP1 or SFRP2 mRNA, and 12 of the 16 lines also did not express SFRP5 mRNA (representative data for eight cell lines are shown in Figure 2 ; Table 1 ). By contrast, expression of all three genes was detected in normal stomach mucosa (Figure 2 ). Treatment with a DNA methyltransferase inhibitor, 5-aza-2 0 -deoxycytidine (5-aza-dC), rapidly restored SFRP expression, strongly indicating epigenetic silencing of SFRP1, SFRP2 and SFRP5 in GC cells (representative data for eight cell lines are shown in Figure 2) .
We next analysed DNA methylation of SFRP genes. We previously identified dense CpG islands in the 5 0 regions of SFRP1, SFRP2 and SFRP5 (Figure 3a) , and so designed two sets of methylation-specific PCR (MSP) primers and bisulfite sequencing primers for SFRP1 and SFRP2, respectively (Figure 3a ). For SFRP5, we designed one MSP primer set and two bisulfite sequencing primer sets. Our MSP analysis revealed methylation of SFRP1 and SFRP2 in all the GC cell lines tested (representative data for eight cell lines are shown in Figure 3b ; Table 1 ). For both genes, the two sets of MSP primers yielded nearly the same results, confirming that the gene promoters were extensively methylated in GC cells (Figure 3b ). SFRP5 was methylated in 13 of 16 (81%) GC cell lines, and there were good correlations between methylation and the expression status (representative data for eight cell lines are shown in Figure 3b ; Table 1 ). One exception was SH101 cells, in which SFRP5 was silenced but no methylation was detected ( Figure 3b ; Table 1) .
In selected samples, we verified the MSP results using bisulfite sequencing (Figure 3c ). The sequencing analysis revealed that the CpG islands of the three SFRP genes were extensively methylated in three GC cell lines that did not express the genes (MKN74, SNU638 and KatoIII), whereas a cell line expressing SFRP5 (MKN1) showed no methylation at any of the cytosines analysed ( Figure 3c ).
One potential mechanism for the tumor-specific lack of SFRP mRNA expression is the inability of the cells to support SFRP transcription owing to a loss of critical transactivation factors or the expression of repressor factors. To assess this possibility, we constructed a set of luciferase reporter vectors that contained upstream regions of SFRP1 and SFRP2 (Figure 4a SFRPs methylation in gastric cancer M Nojima et al two cancer cell lines (HCT116 and SNU638) in which both of the genes were silenced and methylated. Following transient transfection of the three cell lines, we observed high levels of luciferase activity with the pGL3-SFRP1-P3 and P4 vectors, which contain highdensity CpG regions that encompass the presumed transcription start site ( Figure 4b ). We also obtained similar results using luciferase vectors containing SFRP2 promoter sequences, and strong promoter activity was found in a region surrounding the transcription start site of SFRP2 (Figure 4d ). Thus, the SNU638 GC cell line retains the ability to support promoter-driven transcription, and we conclude that the absence of SFRP gene expression is strongly associated with DNA methylation within the promoter-associated CpG islands.
Suppression of TCF/LEF activity and cell growth by ectopic SFRPs expression in GC cells
To examine the relationship between the silencing of SFRP genes and Wnt signaling in GCs, we cotransfected three GC cell lines showing constitutively active Wnt signaling (MKN74, SNU638 and KatoIII) with a TCF/LEF-responsive reporter gene and each SFRP expression vector. MKN74 cells are known to harbor an APC mutation (Sasaki et al., 2001) , whereas CTNNB1 is mutated in SNU638 cells and amplified in KatoIII cells. We found that overexpression SFRP1, SFRP2 or SFRP5 suppressed TCF/LEF activity in all of the GC cells tested (Figure 5a ).
The CRD situated in the N-terminal region of SFRPs reportedly competes with Fz for Wnt binding, thereby modulating Wnt signaling (Jones and Jomary, 2002) . We confirmed this by carrying out reporter assays using SFRP2 deletion mutants lacking either the CRD or the C-terminal netrin-like domain (Figure 5b ). SFRP2 lacking its CRD failed to inhibit TCF/LEF activity, whereas the mutant lacking the netrin-like domain yielded results similar to full-length SFRP2 (Figure 5c ). Apparently, the CRD is necessary and sufficient to repress Wnt signaling in GC cells.
We previously showed that overexpression of SFRPs induces growth inhibition and apoptosis in CRC cells . To examine the effects of SFRPs in GC cells, we transfected each SFRP vector into three GC cell lines (SNU638, MKN45 and NUGC3) and then carried out colony formation assays. After selection with G418 for 2 weeks, we found that introduction of SFRPs markedly suppressed colony formation in all the cell lines tested (Figure 6a and b) . Moreover, flow cytometric analysis confirmed induction of apoptosis in SNU638 and JRST cells transiently transfected with SFRP1, SFRP2 or SFRP5 (Figure 6c ). Apoptosis was also induced by SFRPs in the DLD1 colon cancer cell line, which carries an APC mutation (Figure 6c ).
Changes in gene expression profiles induced by overexpression of SFRP
The present results, which are consistent with our earlier findings 
SFRPs methylation in gastric cancer
M Nojima et al expression of SFRPs inhibits Wnt signaling and induces apoptosis and growth suppression in GC and CRC cells. However, another earlier study showed that direct inhibition of TCF/LEF activity by a dominant-negative mutant (TCF4B) did not affect colon cancer cell growth (Naishiro et al., 2001) . Therefore, in order to further clarify the effect of SFRP, we used oligonucleotide microarrays to assess global changes in the gene expression profile induced by SFRP2. We utilized SNU638 cells because of their high transfection efficiency with electroporation (>70%) and their high TCF/LEF activity, which was successfully suppressed by SFRP2 overexpression ( Figure 5 ). The global changes in gene expression induced by overexpression of SFRP2 in SNU638 cells were determined using the Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA) with approximately 55 000 gene/expressed sequence tag (EST) transcriptions. As compared with an empty vectortransfected counterpart, 411 transcripts were downregulated and 928 transcripts were upregulated by ectopic SFRP2 expression. Of these, genes related to cellular proliferation, growth, apoptosis and Wnt signaling are listed in Table 2 .
Notably, four Wnt signaling target genes were downregulated by SFRP2. LEF1 (Hovanes et al., 2001) , MMP7 (Brabletz et al., 1999) , cyclin D1 (Tetsu and McCormick, 1999) and CD44 (Wielenga et al., 1999) are all reported to be direct or indirect targets of b-catenin-TCF/LEF, confirming that Wnt signaling is blocked by SFRP2 in SNU638 cells (Table 2) . We also found that significant numbers of genes related to cellular proliferation, growth or apoptosis are repressed or induced by SFRP2. For example, GADD45B and GADD45A are two stress response genes, the expression of which induces apoptosis (Takekawa and Saito, 1998) , and PPP1R15A, also known as GADD34, has been implicated in growth suppression and apoptosis. In addition, BCL2-associated athanogene 3 (BAG3), which is also implicated in apoptosis, is an heat shock protein 70 (Hsp70) cochaperone (Takayama and Reed, 2001 ), and we noted that a number of Hsp-70 genes are also upregulated by SFRP2 (Table 2) . % colony numbers % colony numbers % colony numbers S F R P 1 S F R P 2 S F R P 5 V e c t o r S F R P 1 S F R P 2 S F R P 5 V e c t o r SFRPs methylation in gastric cancer M Nojima et al (Figure 7a ), but as MSP is not a quantitative method of analysing methylation, we used bisulfite sequencing to further examine SFRP1 methylation in selected samples. We found that non-tumorous gastric mucosal tissues also harbor methylation of the gene, but the level of methylation of each cytosine was lower than that in tumor tissues (Figure 7b) . To confirm the association between SFRP1 methylation and the gene's silencing in primary GCs, we examined the expression status of SFRP1 using real time RT-PCR with complementary DNA (cDNA) prepared from non-tumorous gastric mucosa from GC patients (n ¼ 15) and primary tumor tissues harboring SFRP1 methylation (n ¼ 16). We found substantial reductions in the levels of expression of SFRP1 mRNA in tumor tissues, but not in the adjacent non-tumorous mucosa (P ¼ 0.0033) (Figure 7c ). Immunohisto chemical analysis revealed an absence of SFRP1 protein expression in GC tissues (representative result in Figure 7d ), whereas positive cytoplasmic staining for SFRP1 was detected in gastric mucosal glands in SFRPs methylation in gastric cancer M Nojima et al adjacent non-tumorous mucosa (a representative result is shown in Figure 7e) . It thus appears that the relatively low level of methylation seen in non-tumorous gastric mucosa from GC patients is not sufficient to silence the gene expression, whereas the higher levels of methylation seen in the tumors are sufficient to do so.
Discussion
Several lines of evidence suggest the Wnt signaling pathway is a major contributor to gastric carcinogenesis, though mutation of APC is not seen in the majority of GCs (Horii et al., 1992; Sasaki et al., 2001 ). In addition, our group has reported that although 16 of 70 (23%) primary GCs showed nuclear and/or cytoplasmic localization of b-catenin, subsequent analysis of 35 tumors revealed no mutation in CTNNB1 (Sasaki et al., 2001) . Other researchers have documented the presence of CTNNB1 mutations in GC with varying frequencies. For example, one group reported that 19.5% (59 of 303) of primary GC tumors showed nuclear accumulation of b-catenin, but CTNNB1 mutation was detected in only 5% (4 of 77) of the tumors (Woo et al., 2001) . Another group analysed 311 primary GCs and observed nuclear b-catenin in 90 tumors (29%). but they subsequently identified CTNNB1 mutations in only 19 of 73 tumors (26%) with nuclear b-catenin, and no mutations were found in 19 tumors without nuclear accumulation (Clements et al., 2002) .
A recent in situ hybridization analysis revealed CTNNB1 gene amplification in KatoIII (Suriano et al., 2005) , and we found boosted TCF/LEF transcriptional activity in the same cells. Thus, CTNNB1 amplification appears to be one mechanism by which b-catenin can be overexpressed, but the frequency of this change in primary GCs is quite low (1 of 49 patients) (Suriano et al., 2005) . AXIN1 mutations are seen more frequently than CTNNB1 mutation in hepatocellular carcinomas in which there is nuclear accumulation of b-catenin , but AXIN1 mutations have not yet been reported in GC, and no mutations were observed in gastro-esophageal junction adenocarcinomas (Koppert et al., 2004) .
In the present study, we first sought to assess Wnt signaling in GC cells using several independent approaches, and then tried to compare the results with already known genetic alterations. Using confocal microscopic analysis, we observed nuclear b-catenin in 13 of 15 GC cells, and membranous staining in 9 cells. Western analysis showed detectable levels of total bcatenin in all GC cell lines tested; however, levels of the activated protein (detected with anti-active-b-catenin antibody) were much more varied and were not detected in four cell lines (MKN1, SNU1, NUGC4 and NCI-N87). TCF/LEF-responsive reporter assays revealed markedly elevated activities in cells with genetic alterations (SNU638, MKN74, KatoIII and AGS), and some of the remaining cell types without genetic changes also showed moderate activation. Taken together, these observations suggest that nuclear b-catenin staining may overestimate Wnt signaling activity and that detection of active b-catenin protein is a more useful way to assess Wnt signaling. It is noteworthy, however, that anti-active-b-catenin antibody sometimes may not be suitable for detecting b-catenin mutants, as it likely failed to detect mutant b-catenin (T41A) in SNU638 cells. We obtained similar results using HepG2 cells, which harbor a deletion in the GSK3b phosphorylation site of CTNNB1 (data not shown).
We previously showed that SFRP1 and SFRP2 are methylated in approximately 90% of CRCs, and about 60% of those tumors also showed SFRP5 methylation (Suzuki et al., 2002) . In the present study, we observed similar frequencies of SFRP methylation in GC cell lines and primary tumors. We also confirmed that restoration of SFRP expression attenuated Wnt signaling, inhibited cell growth and induced apoptosis among GC cells. We therefore propose that a loss of SFRP expression and mutation of downstream components act in concert to boost activity in the Wnt signaling pathway. In cells without APC or CTNNB1 mutations, loss of SFRPs may lead to moderate activation of Wnt signaling; however, we also noted that some GC cells did not show Wnt signaling activity, even though SFRPs were methylated. Given that without Wnt ligands, loss of SFRP function would not be enough to activate the pathway, it is plausible that alterations in Wnt ligands or their receptors may also be important determinants of the signaling activity.
An alternative possibility is that loss of SFRPs contributes to activation of other oncogenic signaling pathways. One recent study showed that SFRP1 is frequently methylated in prostate cancer, and ectopic expression of SFRP1 reduced cellular proliferation, even though b-catenin-TCF/LEF is not activated in prostate cancer cells (Lodygin et al., 2005) . In another study, SFRP4 was found to be methylated in b-catenin-deficient mesothelioma cells, and overexpression of SFRP4 in the cells resulted in apoptosis and growth suppression (He et al., 2005a) . Also, as described above, direct inhibition of TCF/LEF by the dominantnegative mutant TCF4B did not suppress CRC cell growth (Naishiro et al., 2001) . These observations prompted us to survey the changes in the global expression profile induced by SFRP overexpression in cancer cells.
Our microarray analysis confirmed that ectopic expression of SFRP2 repressed Wnt signaling in SNU638 cells by downregulating b-catenin-TCF/LEF target genes. LEF1, cyclin D1, MMP-7 and CD44 are all reportedly Wnt target genes in human CRC cells, and overexpression of cyclin D1 and MMP-7 has been reported in GC (Arber et al., 1999; Ii et al., 2006) . In addition, Saikawa et al. (2001) reported that an antisense oligonucleotide against cyclin D1 inhibited growth of EGF-stimulated GC cells, while MMP-7, also known as matrilysin, is thought to promote cancer cell invasion through its proteolytic activity against components of the extracellular matrix (Ii et al., 2006) . Thus, our data suggest that loss of SFRPs likely contribute to the proliferation and invasiveness of GC cells.
The global expression analysis also revealed that SFRPs induce changes in the expression of numerous genes related to cellular growth or apoptosis. For example, GADD45B and GADD45A are induced by environmental stresses, and they in turn induce p38/ JNK activation and apoptosis (Takekawa and Saito, 1998) . In addition, PPP1R15A (GADD34) is regulated by genotoxic stress and nutrient deprivation during myeloid differentiation (Hollander et al., 2003) . Expression of GADD34 correlates with apoptosis induced by various signals, and its overexpression can elicit apoptosis (Hollander et al., 2003) . By contrast, BAG3 was first identified as a BAG1-related protein and is known to modulate anti-apoptotic activity. The BAG family proteins are Hsp70 co-chaperones and are characterized by the BAG-domain that interacts with the ATPase domain of Hsp70 (Takayama and Reed, 2001) . Interestingly, we also observed that SFRP2 induces a number of Hsp70 genes, including HSPA6, HSPA1A and HSPA1B. Moreover, we carried out a second microarray analysis, which revealed that overexpression of SFRP2 also induced the PPP1R15A, BAG3 and Hsp70 genes in the DLD1 CRC cell line (data not shown). As the majority of the genes on our list are not implicated in Wnt signaling, it is not clear how SFRPs induce changes in the expression of these genes, and much about how SFRPs induce apoptosis remains unclear. Nevertheless, our data and the studies of other groups indicate that growth suppression and apoptosis induced by SFRPs can be mediated by a mechanism independent of the b-catenin-TCF/LEF pathway.
Finally, our results suggest that blockade of Wnt ligand may exert a therapeutic effect in the treatment of GC. One recent study reported that anti-Wnt1 antibody attenuated Wnt signaling and induced apoptosis in CRC cells carrying APC or CTNNB1 mutations (He et al., 2005b) . Wnt and Fz also have been shown to be potential targets for immunotherapy in head and neck squamous cell carcinomas (Rhee et al., 2002) . And the frequent SFRP methylation seen in non-cancerous gastric mucosa from GC patients suggests that methylation occurs at an early stage of gastric tumorigenesis. Taken together, these data suggest that Wnt blockade or restoration of SFRP function may provide a useful new approach to treating GCs.
Materials and methods

Cell lines and tissues
Thirteen GC cell lines (MKN1, MKN7, MKN28, MKN45, MKN74, SH101, SNU1, SNU638, JRST, KatoIII, AZ521, NUGC3 and NUGC4) and two CRC cell lines (HCT116 and DLD1) were obtained as described previously Toyota et al., 2003) . Three others (AGS, NCI-N87 and SNU16) were obtained from the American Type Culture Collection (Manassas, VA, USA). All of the cell lines were cultured in the appropriate medium. To analyse restoration of SFRP genes, cells were treated with 2.0 mM 5-aza-dC (Sigma) for 72 h, replacing the drug and medium every 24 h. A total of 46 primary GCs and adjacent non-tumorous gastric mucosa were obtained as described . Genomic DNA was extracted using the standard phenol-chloroform procedure. Total RNA was extracted by using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and then treated with a DNA-free kit (Ambion, Austin, TX, USA). Total RNA from normal gastric mucosa from a healthy individual was purchased from BioChain (Hayward, CA, USA).
RT-PCR
Single-stranded cDNA was prepared using SuperScript III reverse transcriptase (Invitrogen). The integrity of the cDNA was confirmed by amplifying glyceraldehydes-3-phosphate dehydrogenase (GAPDH). The PCR protocol entailed 5 min at 951C; 35 cycles of 1 min at 951C, 1 min at 551C and 1 min at 721C; and a 7 min final extension at 721C. Primer sequences and PCR product sizes are shown in Supplementary Table 1 .
Methylation analysis
Bisulfite treatment of genomic DNA was carried out as described previously (Suzuki et al., 2002) . Methylation of SFRPs was analysed using MSP and bisulfite-sequencing analysis as described previously . PCR was run in a volume of 25 ml containing 1 Â MSP buffer (67 mM Tris-HCl (pH8.8), 16.6 mM (NH 4 ) 2 SO 4 , 6.7 mM MgCl2 and 10 mM 2-mercaptoethanol), 1.25 mM deoxyribonucleoside triphosphate, 0.4 mM each primer and 0.5 U of JumpStart REDTaq DNA polymerase (Sigma, St Louis, MO, USA). The PCR protocol for MSP entailed: 5 min at 951C; 35 cycles of 30 s at 951C, 30 s at 601C and 30 s at 721C; and a 7 min final extension at 721C. The PCR protocol for bisulfite-sequencing entailed: 5 min at 951C; 35 cycles of 1 min at 951C, 1 min at 601C and 1 min at 721C; and a 7 min final extension at 721C. Amplified bisulfite-sequencing PCR products were directly sequenced by using an ABI3100 automated sequencer (Applied Biosystems, Foster City, CA, USA). Primer sequences and PCR product sizes are given in Supplementary Table 1 .
Western blotting
Western analysis was carried out as described previously (Murai et al., 2005) . Anti-b-catenin antibody was purchased from BD Transduction Laboratories (San Diego, CA, USA). Anti-active-b-catenin antibody (clone 8E7), which is specific for b-catenin dephosphorylated on Ser37 and Thr41, was from Upstate (Lake Placid, NY, USA). Anti-GAPDH antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Immunofluorescence microscopy Cells cultured on chamber slides were washed with phosphatebuffered saline (PBS) and fixed with 4% paraformaldehyde, after which they were incubated with anti-b-catenin monoclonal antibody (BD Transduction Laboratories) and stained with anti-mouse IgG Alexa Fluor 488 (Invitrogen). Cells were examined using an FV300-IX71 confocal laser scanning microscope (Olympus, Tokyo, Japan).
TCF/LEF reporter assay
Reporter assays with pGL3-OT, a TCF/LEF-responsive luciferase reporter plasmid, and pGL3-OF, a negative control plasmid, were carried out as described previously . Briefly, cells (5 Â 10 4 cells/well in 24-well plates) were transfected with 100 ng of pGL3-OT or pGL3-OF and 2 ng of pRL-CMV using Lipofectamine 2000 (Invitrogen). For co-transfection experiments, cells were transfected with 100 ng of one of the pCMV-HA-SFRP vectors plus the reporter plasmid. A series of SFRP expression vectors and SFRP2 deletion mutant constructs were prepared as described previously . Firefly and renilla luciferase activities were measured 48 h after transfection using a DualLuciferase Reporter Assay System (Promega, Madison, WI, USA) and a Lumat LB 9507 luminometer (Berthold Technologies, Bad Wildbad, Germany). Promoter reporter assay Upstream regions of SFRP1 and SFRP2 were amplified by PCR and then cloned into pCR2.1 TOPO (Invitrogen). Each forward PCR primer carried a 5 0 overhang that contained an MluI recognition site, and each reverse primer contained a BglII site. After verifying the sequences, fragments were cut using MluI and BglII and ligated into pGL3-Basic (Promega). Cells (5 Â 10 4 cells/well in 24-well plates) were transfected with 100 ng of one of the reporter plasmids and 2 ng of pRL-TK (Promega) using Lipofectamine 2000 (Invitrogen). A pGL3-Basic vector without insert served as a negative control. Luciferase activities were measured 48 h after transfection using a Dual-Luciferase Reporter Assay System (Promega).
Colony formation assay Cells (2 Â 10 6 cells) were transfected with 5 mg of one of the pcDNA3.1His-SFRP vectors or with empty vector using a Cell Line Nucleofector kit V (Amaxa, Cologne, Germany) and a Nucleofector I electroporation device (Amaxa) according to manufacture's instructions. A set of SFRP vectors were prepared as described previously . Cells were then plated on 60-mm culture dishes and selected for 14 days with 0.6 mg/ml G418. Colonies were then stained with Giemsa, and counted using National Institute of Health IMAGE software.
Flow cytometry
Flow cytometry was carried out as described previously . Briefly, cells (2 Â 10 6 cells) were transfected with 5 mg of one of the pCMV-HA-SFRP vectors or with empty vector using the Cell Line Nucleofector kit V (Amaxa) and a Nucleofector I electroporation device (Amaxa). The cells were then harvested 72 h after transfection and analysed using a FACSCalibur instrument (Becton Dickinson, San Jose, CA, USA).
Microarray analysis SNU638 cells (2 Â 10 6 cells) were transfected with 5 mg of either pCMV-HA-SFRP2 or empty vector using a Cell Line Nucleofector kit V (Amaxa). The cells were then harvested 24 h after transfection, and total RNA was prepared as described above. Synthesized cRNA was hybridized to the Human Genome U133 Plus 2.0 Array (Affymetrix) with approximately 55 000 gene/EST transcriptions.
Real-time RT-PCR
Real-time RT-PCR was carried out using TaqMan Gene Expression Assays (Applied Biosystems) and a 7900HT Fast Real-Time PCR System (Applied Biosystems) according to the manufacture's instructions. SDS2.1 software (Applied Biosystems) was used to perform comparative DC t analysis. GAPDH served as endogenous controls.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of gastric carcinomas and adjacent non-tumorous gastric mucosa from five patients were heated in 10 mM sodium citrate in a microwave oven at maximum power for 15 min and then at a reduced power for 15 min to achieve antigen recovery. After the sections were blocked in a 5% solution of bovine serum albumin in PBS also containing 0.5% Tween-20, they were incubated with a goat anti-SFRP1 polyclonal antibody C-19 (1:100 dilution; Santa Cruz) overnight at 41C. The sections were then developed using EnVision-Plus reagents (Dako, Glostrup, Denmark); 3,3 0 -diaminobenzidin served as the chromogen. Finally, the sections were counterstained with hematoxylin, and microscopic images were captured digitally.
